

Corrigendum

Corrigendum to “Imatinib: A Breakthrough of Targeted Therapy in Cancer”

Nida Iqbal¹ and Naveed Iqbal²

¹Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India

²Department of Anaesthesia and Intensive Care Unit, Indraprastha Apollo Hospital, New Delhi 110076, India

Correspondence should be addressed to Nida Iqbal; nida.iqbal55@yahoo.com

Received 15 September 2020; Accepted 15 September 2020; Published 28 December 2020

Copyright © 2020 Nida Iqbal and Naveed Iqbal. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The article titled “Imatinib: A Breakthrough of Targeted Therapy in Cancer” [1] was found to contain material from previously published work, mainly in sections 3.1, 3.3, 3.4, 3.5, and 3.6. The articles are as follows:

- (i) S. A. Khan, “Targeted therapies for philadelphia chromosome-positive acute lymphoblastic leukemia,” *School of Pharmacy*, 37, 5 (Oncology suppl): 3–7, 2012 (<https://www.uspharmacist.com/article/targeted-therapies-for-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia>) [2] (not cited).
- (ii) A. Olivieri, M. Cimminiello, P. Corradini, et al., “Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD,” *Blood*, 2013, doi: <https://doi.org/10.1182/blood-2013-05-494278> (<http://www.bloodjournal.org/content/122/25/4111>) [3] (cited as reference 56).
- (iii) C. Ustun, D. L. DeRemer, and C. Akin, “Tyrosine kinase inhibitors in the treatment of systemic mastocytosis,” *Leukemia Research*, 2011, doi: <https://doi.org/10.1016/j.leukres.2011.05.006> ([https://www.lrrjournal.com/article/S0145-2126\(11\)00223-2/fulltext](https://www.lrrjournal.com/article/S0145-2126(11)00223-2/fulltext)) [4] (not cited).
- (iv) S. Verstovsek, “New Hematological Indications for Imatinib,” *Hematological Cancer*, 2007, doi: <http://doi.org/10.17925/OHR.2007.00.2.36> (<https://www.toucho>

[ncology.com/articles/new-hematological-indications-imatinib](https://www.toucho)) [5] (not cited).

- (v) M. Breccia and G. Alimena, “Resistance to Imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem,” *Cardiovascular and Hematological Disorders-Drug Targets*, 2009, doi: <https://doi.org/10.2174/187152909787581363> (<http://www.eurekaselect.com/68887/article>) [6] (not cited).

References

- [1] N. Iqbal and N. Iqbal, “Imatinib: a breakthrough of targeted therapy in cancer,” *Chemotherapy Research and Practice*, vol. 2014, Article ID 357027, 9 pages, 2014.
- [2] S. A. Khan, “Targeted therapies for philadelphia chromosome-positive acute lymphoblastic leukemia,” *School of Pharmacy*, vol. 37, no. Oncology suppl, pp. 3–7, 2012.
- [3] A. Olivieri, M. Cimminiello, P. Corradini et al., “Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD,” *Blood*, vol. 122, no. 25, pp. 4111–4118, 2013.
- [4] C. Ustun, D. L. DeRemer, and C. Akin, “Tyrosine kinase inhibitors in the treatment of systemic mastocytosis,” *Leukemia Research*, vol. 35, no. 9, pp. 1143–1152, 2011.
- [5] S. Verstovsek, “New hematological indications for Imatinib,” *Oncology & Hematology Review (US)*, vol. 1, no. 2, pp. 36–39, 2007.
- [6] M. Breccia and G. Alimena, “Resistance to Imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem,” *Cardiovascular & Hematological Disorders-Drug Targets*, vol. 9, no. 1, pp. 21–28, 2009.